Tissue factor pathway inhibitor (TFPI) is a plasma Kunitztype serine protease inhibitor that directly inhibits coagulation Factor Xa and also inhibits tissue factor-initiated coagulation. Normal human plasma TFPI exists both as the fulllength molecule and as variably carboxy-terminal truncated forms. We reported recently that the low density lipoprotein receptor-related protein mediates the cellular degradation of TFPI after TFPI binding to the hepatoma cell surface. To examine whether the carboxy terminus of TFPI was required for interacting with hepatoma cells, a mutant of TFPI lacking the third Kunitz-type domain and basic carboxy terminus was generated. We found that this mutant, TFPI-160, did not compete with full-length '"I-TFPI-160 for binding to hepatoma cells. We were also unable to demonstrate specific binding of '"I-TFPI-160 to hepatoma cells at 40C. At 370C, significantly less '"I-TFPI-160 was internalized and degraded via low density lipoprotein receptor-related protein than full-length '"I-TFPI. Full-length '"I-TFPI binding to hepatoma cells could be inhibited > 90% by heparin and other highly charged molecules. Since TFPI, but not TFPI-160, was capable of effectively binding to cultured hepatoma cells, the fates of TFPI and TFPI-160 in vivo were examined. Both '"I-TFPI and '"I-TFPI-160 disappeared rapidly from the circulation after their intravenous administration into rats. The initial plasma half-life of '"I-TFPI was -30 s whereas the half-life of 1"I-TFPI-160 was -4 min. 'I-TFPI was cleared predominantly by the liver. In contrast, '"I-TFPI-160 accumulated in the outer cortex of the kidney. Using microscopic autoradiography, we demonstrate that 1"I-TFPI clearance is largely hepatocellular, whereas 1"I-TFPI-160 accumulates mainly in the cells of the kidney proximal tubules. Together our findings demonstrate that the carboxy-terminal region(s) distal to amino acid 160 of TFPI mediates TFPI binding to hepatoma cells both in vitro and in vivo. (J. Clin. Invest. 1995.95:1773
Introduction
Tissue factor pathway inhibitor (TFPI)' is a trace 40-kD plasma glycoprotein (-2.0 nM) that plays a key role in the regulation of tissue factor (TF)-initiated blood coagulation (1, 2) . TFPI was initially identified after the observation that preincubation of TF with serum prevented the lethal disseminated intravascular coagulation that occurs after TF infusion in animals (3, 4) . This observation suggested there was an inhibitor of TF in serum. This serum inhibitor, currently called T1PI, was subsequently purified from various sources including human hepatoma HepG2 cells (5, 6) , plasma lipoproteins (7), and postheparin plasma (8) . The cDNA was cloned from human placental and fetal liver cDNA libraries (9) . Mature TEPI, 276 residues, contains an acidic amino-terminal domain followed by three tandem Kunitz-type protease inhibitory domains, and a basic carboxy-terminal domain (9) .
TFPI regulates coagulation via its abilities to directly inhibit coagulation Factor Xa and to inhibit the Factor Vlla-TF complex of the extrinsic pathway of blood coagulation ( 10) . The extrinsic pathway of coagulation is initiated when damage to blood vessels at the site of a wound allows TF to gain access to the plasma. Plasma Factor VII or VIla binds to TF and the Factor VIla-TF complex proteolytically activates Factors IX and X, triggering a cascade of events which eventually leads to the generation of thrombin and the formation of a fibrin clot (1, 2) . Inhibition of the Factor VIIa-TF complex by TFPI occurs in two steps. In the first step, Factor Xa binds to the second Kunitz-type domain of TFPI, and in the second step, the TFPI-Factor Xa complex binds to the TF-Factor VIla complex through an interaction between the first Kunitz-type domain and Factor VIla, forming a Factor Xa-TFPI-Factor VIla-TF complex ( 11 ) . The function of the third Kunitz-type domain is not known.
The majority of circulating TFPI is not in the form of the full-length molecule but is truncated at various positions in its carboxy terminus (12) . The enzyme(s) responsible for carboxy-terminal truncation has not been identified and whether proteolysis modulates TFPI activity in vivo is also not known. Using a carboxy-terminal truncated variant of TFPI lacking the third Kunitz-type domain and basic carboxy terminus (TFpI1-161 ), Hamamoto et al. (13) reported that TFPI 1-161 inhibited cell surface Factor VIla-TF proteolytic activity towards Factor X identically to full-length TEPI. Carboxy-terminal truncated TFPI and full-length TFPI have also been shown to inhibit Factor Xa and Factor VIla-TF equally in endpoint-type assays (14) . However, carboxy-terminal truncated TFPI possesses considerably less anticoagulant activity as measured in one stage coagulation assays because full-length TFPI is a more potent inhibitor of the prothrombinase complex (14-16).
After the intravenous administration of TFPI into rabbits, TFPI is rapidly cleared from the circulation (initial tI/2 of-2 min) and accumulates in the liver and kidney (17, 18) . Bregengaard et al. (18) reported that the carboxy terminus of TFPI was important in mediating rapid TFPI clearance because 2 min after intravenous injection the recovery in plasma of TFPI'-61 was 15-fold higher than full-length TFPI. Heparin, which binds to the basic carboxy terminus of TFPI and to a portion of the third Kunitz-type domain (14, 15), was found to reduce the clearance of full-length TEPI -10-15-fold but had no effect on the clearance of TFPI'-16' (18) .
Using hepatoma cell lines, we reported recently ( 19) Proteins. Recombinant human full-length TFPI (containing the basic carboxy terminus) was a gift from the Monsanto Co. (Chesterfield, MO). A cDNA encoding a truncated form of TFPI (TFPI-160) was constructed in which the codon triplet for glycine 160 was followed by two consecutive TGA stop codons and an appropriate HindIH restriction site. This cDNA was inserted into the pMON6875 expression vector and the production of TFPI-160 in Escherichia coli was essentially as described for full-length TFPI except that the sample was reapplied to a Q Sepharose fast flow column (Pharmacia LKB Biotechnology Inc., Piscataway, NJ), pH 8.0, instead of a mono S column in the final purification step (20) . After SDS-PAGE and staining with Coomassie brilliant blue, TFPI-160 migrates as a single band of 22 kD. a2-Macroglobulin was purified from human plasma and activated by incubation with methylamine (to yield a2M*) (21) . The full-length rat 39-kD protein and constructs encoding residues 1-114 and 115-319 of the 39-kD protein were produced as fusion proteins with glutathione Stransferase (GST) in E. coli. The GST fusion proteins were purified by glutathione-agarose chromatography (21) . The full-length GST 39-kD protein was cleaved with thrombin and free 39-kD protein was purified via heparin-agarose chromatography (21) .
Antibodies. Polyclonal rabbit antibodies were generated against fulllength human TFPI and total IgG was prepared using protein A-agarose (14). 10 ,l of 0.5 M EDTA. Each of the blood samples was centrifuged, and 10-20 Il of the plasma fractions was spotted onto 3-mm filter paper (Whatman Inc., Clifton, NJ), precipitated with 10% trichloroacetic acid, rinsed with ethanol, and '"I-radioactivity was determined. The initial plasma concentrations (time = 0) of '`I-TFPI and '"I-TFPI-160 were obtained by extrapolating the amount of radioactivity from the first two (TFPI) or six (TFPI-160) measured samples. At the times specified in the text, the animals were killed and the liver, kidneys, and spleen were removed, blotted, weighed, and '25I-radioactivity was determined.
Autoradiography. Samples of the kidneys and livers from rats injected with '25I-TFPI or "'I-TFPI-160 were fixed with 10% phosphatebuffered formalin and embedded in paraffin. Sections were then stained with hematoxylin and eosin and examined microscopically to delineate grain distributions.
Immunoprecipitations. Plasma samples from the indicated time points of rats injected with '"I-TFPI (25 td) or '25I-TFPI-160 (15 Al) or 100,000 cpm of starting '"I-TFPI and '"I-TFPI-160 were mixed with PBS (final volume 500 sl) and immunoprecipitated with 10 Ag of total anti-TFPI IgG/sample at 4°C for 4 h (TFPI samples) or overnight (TFPI-160 samples). 60 tl of a 50% slurry of protein A-agarose was added for 2 h at 4°C. Nonspecifically bound radioactivity was removed by washing the protein A-agarose beads three to four times with PBS containing 1% (vol/vol) Triton X-100, 0.5% (wt/vol) sodium deoxycholate, 1% (wt/vol) SDS, and 0.5% (wt/vol) BSA. The immunoprecipitated material was released from the beads by boiling each sample for 5 min in 62.5 mM Tris-HCl, pH 6.8, 2% (wt/vol) SDS, 10% (wt/vol) glycerol, and 5% (vol/vol) 2-mercaptoethanol (Laemmli sample buffer) (23) . The entire plasma immunoprecipitates and 10,000 cpm of the starting immunoprecipitates were subjected to 12.5% SDS-PAGE. The gels were fixed, dried, and exposed to film.
Results
Effect of the 39-kD protein on the cellular degradation and cellular association of l25sITFPI and '25I-TFPI-160. We reported previously that LRP mediates the cellular degradation of '25I-TFPI after 125 I-lFPI binding to the hepatoma cell surface (19) . To examine whether the carboxy terminus of TFPI was important for interacting with hepatoma cells/LRP, a construct encoding amino acids 1-160 of TFPI was produced in E. coli and purified. This construct, TFPI-160, consists of the first two Kunitz-type domains of TFPI and lacks the third Kunitz-type domain and basic carboxy terminus. The ability of the 39-kD protein to alter LRP-mediated degradation of 125IJTFpI4160 was examined by incubating rat hepatoma MH1C1 cells with 10 nM '"I-TFPI-160 in the absence or presence of increasing concentrations of the 39-kD protein for 4 h at 37°C. As a control, 2.5 nM of full-length 125I-'TPI was similarly incubated with MHIC1 cells. Thereafter, the medium overlying the cell monolayers was subjected to trichloroacetic acid precipitation, and trichloroacetic acid-soluble radioactivity, representing degraded ligand, was determined. As seen in Fig. 1 A and as demonstrated previously ( 19) , the 39-kD protein inhibits the cellular degradation of '"I-TFPI in a dose-dependent manner. The Ki value2 for inhibition is -70 nM. Degradation of 125I-TFPI (initial concentration 2.5 nM) is reduced from 308 fmol/mg protein in the absence of the 39-kD protein to 65 fmol/mg protein in the presence of 1 ,uM 39-kD protein. The 39-kD protein also inhibits the cellular degradation of 125I-'l';I4160 (initial concentration 10 nM) in a dose-dependent manner. Degradation is reduced from 89 fmol/mg protein in the absence of the 39-kD protein to 18 fmol/mg protein in the presence of 1 uM 39-kD protein.
We next examined whether the 39-kD protein alters the cellular association of '25I-TFPI and 125I-TFPI-160. After incubation at 37°C for 4 h, the overlying medium was removed and the cells were rinsed to remove unbound ligand. Cells were then lysed in a buffer containing 0.2% SDS, and radioactivity of the cell lysates was determined. Fig. 1 B demonstrates that the 39-kD protein has no effect on the cellular association of '"'I-TFPI. The cellular association of 125I-FPI-160 (initial concentration 10 nM), however, is reduced from 55 fmol/mg protein in the absence of the 39-kD protein to 17 fmol/mg protein in the presence of 1 MM 39-kD protein.
We reported previously that LRP is not the major receptor for TFPI on the hepatoma cell surface since the 39-kD protein did not inhibit 125I-'FPI binding at 4°C (19) . The inability of the 39-kD protein to inhibit the cellular association of '"I-TFPI 
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at 370C (Fig. 1 B) also suggests that the majority of TFPI is not associating with LRP. To examine whether the 39-kD protein was altering the intracellular association of '"I-TFPI (and 12514TFp1J160) with LRP, cell monolayers were treated with Pronase after incubation for 4 h at 37°C. Pronase treatment digests cell surface radioligand, thereby separating surface (Pronase-sensitive) from internalized radioligand (Pronase-resistant) (24) . As seen in Fig. 1 C, the 39-kD protein has no effect on cell surface-associated '"I-TFPI but does inhibit, in a dosedependent manner, 125WI-TFPI internalization (Fig. 1 D) . Fig. 1 C also shows that the 39-kD protein inhibits the cell surface association of 125IJFJI-160 (initial concentration 10 nM) by 50% (17 fmol/mg protein in the absence of the 39-kD protein vs 9 fmol/mg protein in the presence of 1 OM 39-kD protein).
Internalization of '25 I-TFPI-160 (Fig. 1 D) is also inhibited by the 39-kD protein (38 fmol/mg protein in the absence of the 39-kD protein vs 9 fmol/mg protein in the presence of 1 jIM 39-kD protein). Fig. 1 , B and C, also demonstrates that in the absence of the 39-kD protein significantly less '25I-TFPI-160 is associated with hepatoma cells than full-length 1254I-TFPI.
Inhibition of '251-TFPI-160 internalization by 39-kD protein constructs. To define whether the amino and/or carboxy terminus of the 39-kD protein is responsible for inhibiting l251jjFpj_ 160 internalization, MH1C1 cells were incubated for 4 h at 37°C with various concentrations of GST fusion proteins encoding residues (GST/1-114) and residues 115-319 (GST/ 115-319) of the 39-kD protein. Thereafter, the overlying medium was removed and the cell monolayers were rinsed and treated with Pronase. Effect of TFPI and TFPI-160 on the binding, cellular association, and cellular degradation of l25I-a2M*-We reported previously that TFPI inhibits the binding and degradation of l"I-a2M* by MH1C1 cells.3 Therefore we compared the ability of TFPI with TFPI-160 to alter l"5I-a2M* binding at 4°C and to alter the cellular association/degradation of '"I-a2M* at 37°C. Fig. 3 (Fig. 3 B) and cellular degradation of 125I-a2M* (Fig. 3 C) at 37°C, whereas 1 tiM TFPI-160 inhibits -10% of 125I-a2M * degradation.
Binding of 125I-TFPI and l25I-TFPI-160 to hepatoma cells. hepatoma cells in vitro, the fates of T`FPI and TFPI-160 were examined in vivo. Approximately 6-8 x 106 cpm of '25I-TFPI and 25I-'FPI-160 was intravenously injected into the tail veins of rats. The disappearance of "25I-radioactivity (trichloroacetic acid-precipitable) from rat plasma was followed over time. injection, the percentages of '5I-TFPI associating with the liver, kidneys, and spleen were 25, -2, and < 1% of the injected dose, respectively (Table I) . Fig. 6 A also shows that 125I-TFPI-160 disappears rapidly from the circulation after intravenous administration. '25I1_FPI 160 clearance was linear over 10 min and the plasma half-life was -4 min. At 10 min, -20% of the injected dose remained in the circulation. The amount of 125I-lTEPI-160 associating with the liver, kidneys, and spleen was determined 10 min (n = 2 rats), 15 min (n = 1 rat), and 35 min (n = 1 rat) after intravenous administration of 125I1 TFPI-160. The organ distributions were similar at the three time points and were therefore averaged. As seen in Table I , and in Seven rats were injected with 6-8 x 106 cpm of '"'I-TFPI. After 10 min, the animals were killed, organs were obtained, and their content of '"I-radioactivity was determined. Four rats were injected with 6-8 x 10 cpm of '"I-TFPI-160. After 10 min (n = 2 rats), 15 min (n = 1 rat), or 35 min (n = 1 rat), the animals were killed and "2I-radioactivity associating with the liver, kidneys, and spleen was determined. n, number of animals in each group. Data are expressed as meantSEM.
marked contrast to the results with '25I-TFPI, 9 , 77, and 1% of the injected '"'I-TFPI-160 accumulated in the liver, kidneys, and spleen, respectively. Plasma samples obtained 1, 4, and 10 min after the intravenous administration of '5I-TFPI and '25I-TFPI-160 into rats were subjected to immunoprecipitation with anti-TEPI antibodies. After SDS-PAGE and autoradiography, both '`I-TFPI and '25I-TFPI-160 were found to migrate identically to the starting '251-labeled proteins (Fig. 6 B) . Fig. 6 B also shows that the disappearance of '25I-TlFI and 125I-TFPI-J160 over time on SDS-PAGE parallels the disappearance seen in Fig. 6 A. Furthermore, 125I-FP1 could be immunoprecipitated from plasma samples obtained 1, 4, and 10 min after intravenous administration using a carboxy-terminal antipeptide rabbit antibody generated against amino acids 265-276 of TFPI (14) (data not shown). These results demonstrate that full-length TEPI is not being proteolyzed at the carboxy terminus for at least 10 min after its intravenous administration.
Sites of'25I-TFPI and 125I-TFPI-160 clearance. Tissue sections of kidney and liver were prepared after the in vivo administration of 6-8 x 106 cpm of l25IjTFpI and 125IflTFIj_160. 255I-Radioactivity localizes to the outer cortex of the kidney in rats injected with 1"I-TFPI (Fig. 7 A) and '25I-TFPI-160 (Fig. 7 B). The intensity of radioactivity is substantially greater in the kidneys of rats injected with 25I-flFI-160 than in rats injected with 125I-TFPI. The patterns of radioactivity in the livers from rats injected with "5I-TFPI and '25I-lTFI-160 were homogenous. The intensity of radioactivity was substantially greater in the livers of rats injected with 1"I-TFPI than in rats injected with "25I-1FI-160. To examine which cell type (s) in the kidney and liver accumulated 125I-TFPI and 125I-TFPI-160, kidney and liver sections were prepared 10 min after their intravenous injections and examined by microscopic autoradiography. Fig. 8 A (x300, 3-wk exposure) is a hematoxylin and eosin-stained autoradiogram of a kidney section from a rat injected with '"I-TFPI. The grains localize both to the glomeruli and to the cells of the proximal tubules (predominantly on the apical surface).
Autoradiograms of kidney sections from a rat administered '"I-TFPI-160 are seen in Fig. 8 Moreover, after intravenous administration of '25I-TFPI and '25I-TFPI-160 into rats, '25I-TFPI accumulates predominantly in the liver, whereas 125I-T'T-PI-160 accumulates in the outer cortex of the kidneys. The clearance curve we obtained after injection of tracer doses of full-length 125I-TFPI into rats is similar to those described previously after bolus or tracer dose administration of TFPI into rabbits (17, 18, 25) , baboons (26) , and rats (27) in that the alpha phase of clearance is extremely rapid. The reported beta phase half-lives vary from 17 min to 2 h (17, 18, 26) . The recoveries of TFPI in plasma between 10 min and 4 h after intravenous administration also vary (from -3 to -40%) and may reflect differences in the TFPI preparations administered (17, 18, (25) (26) (27) . We found that between 1 and 10 min, -20% of the injected 125I-T'FI was still remaining in the circulation (Fig. 6 A) , and at 10 min, 25% was associated with the liver. It is not clear where the remaining 55% of injected 125I-TPFI accumulates. Circumstantial evidence suggests that TFPI may be bound to heparan sulfate proteolglycans or glycosaminoglycans on the endothelial cell surface. This hypothesis is based on the observations that: (a) TFPI binds to heparin agarose (14); (b) heparin and sulfated polysaccharides enhance the anticoagulant activity of TFPI (28) ; and (c) after intravenous administration of heparin, plasma levels of TFPI increase severalfold (8, 29) . Thus it is possible that the 55% of '"I-TFPI is bound to the vascular endothelium in various tissues. The observation that the vast majority of 125I-TFPI clearance was hepatocellular and not associated with the hepatic vascular endothelium (Fig. 8 E) , however, argues against 125I-TFPI being bound to the vascular endothelium.
In sharp contrast to the hepatocellular accumulation of 125I-TFPI, '25I-'FPI-160 accumulated mainly in the cells of renal proximal tubules (Fig. 8, B-D) . The small fraction of '"I-TFPI that associated with the kidneys also localized to the proximal tubules as well as to the glomeruli (Fig. 8 A) . The vastly different tissue distribution observed with TFPI and TFPI-160 suggests that the third Kunitz-type domain and/or carboxy terminus confers liver specificity. It is also possible that the acidic amino terminus and/or first two Kunitz-type domains confers kidney specificity. It is not clear whether TFPI and TFPI-160 are being filtered/reabsorbed. It is also not clear whether TFPI and TlFPI-160 are binding specifically to a renal protein although a likely candidate would be glycoprotein 330 (gp330), a member of the LDL-receptor family that localizes to clathrin-coated pits of kidney proximal tubules and glomerular epithelium (30) (31) (32) . It is interesting to note that a2M* does not bind to gp330 (33, 34) , and that TFPI-160, which associates with the kidney after intravenous administration, only slightly alters the binding and cellular degradation of 125I-a2M *. The potential involvement of gp330 in the endocytic internalization of TFPI and TFPI-160 will be the subject of future studies.
We reported previously that, after TFPI binding to the hepatoma cell surface, LRP mediates the cellular degradation of TFPI since both antibodies directed against LRP as well as the full-length 39-kD protein or residues 115-319 of the 39-kD protein each inhibit > 80% of 125I'TFPI degradation (19) .3 In addition, we reported that LRP was not the major hepatic cell surface receptor for TFPI since '25I-rFPI binding at 4°C was not inhibited by the 39-kD protein (19) . In the current study, we found '25I-TFPI internalization (Pronase-resistant) but not the total cellular association (i.e., cell surface plus internalized) or cell surface association (Pronase-sensitive) of '25I-TFPI could be inhibited by the 39-kD protein. This is consistent with the notion that the majority of 125I-TFPI is not binding to LRP but that TFPI uptake and degradation occurs via LRP.
Since TFPI-160, which lacks the basic heparin-binding carboxy terminus of TFPI, did not bind to hepatoma cells, we examined whether heparin and related negatively charged molecules altered '25I-TFPI binding. We found that heparin, as well as other sulfated polysaccharides, inhibited 125I-TFPI binding. However, it is not clear at present whether inhibition resulted from direct competition for the cell surface TFPI-binding pro- We reported previously that carboxy-terminal residues 1 15-319 of the 39-kD protein, generated as a fusion protein with GST, inhibit the cellular degradation of 125I-WFPI essentially identically to the full-length 39-kD protein, GST/1-319.3 Although the 40C binding assays demonstrated that TFPI-160 did not interact with hepatoma cells to a substantial degree (Fig.  4) , we examined whether TFPI-160 was capable of interacting with LRP by testing whether the 39-kD protein altered TFPI-160 degradation by cultured hepatoma cells. After incubation at 370C, we found that the 39-kD protein inhibited the cellular association, internalization, and degradation of 1251I-TFPI-160 (Fig. 1, B-D) . Similar to the results obtained with full-length TFPI, residues 115-319 of the 39-kD protein inhibited TFPI-160 internalization essentially identically to the full-length 39-kD protein (Fig. 2) . The relative amount of TFPI-160 inoealized and degraded, however, was markedly less than that seen with full-length TFPI. This suggests that the third Kunitz-type domain and/or the basic carboxy terminus contains residues important for interaction with LRP. Alternatively, it is possible that TFPI may be optimally recognized by LRP only while bound to the primary TFPI-binding species.
